Newsletter Subject

Smart Money Moving In On This Deal

From

biotechbreakouts.com

Email Address

kyle@biotechbreakouts.com

Sent On

Thu, Apr 30, 2020 02:00 PM

Email Preheader Text

Dear Undefined, Any moment now I’ll be releasing a brand new . This is just the fifth time Iâ?

Dear Undefined, Any moment now I’ll be releasing a brand new [Sniper Report alert](. This is just the fifth time I’ve released a special report since launching the service more than two years ago. Why? I’m up over a million dollars this year from trading. For me to put on a buy-and-hold position, it has to grab my attention and smack me over the head with a two by four. And that’s exactly what I’m feeling right now. However, with the market heating up and this stock moving along with it, I’m afraid I might miss it. That’s why I wanted to give you one more opportunity to get involved. Here’s the deal: About a few months ago Volkswagen, one of the largest automakers in the world announced that it would be making a strategic acquisition ([the stock I will be buying and highlighted in my special report](). However, when the COVID-19 pandemic hit the deal was put on pause. Like the rest of the market, the stock dropped, but has since been staging a comeback. But there is still plenty of more upside here. You see, it’s still trading 46% off the expected deal price. In My Eyes, It Feels Like Free Money Waiting To Be Taken But time is of the essence here. If and when the deal is back on, the stock can instantly shoot up to the expected deal price. It’s extremely rare to see a merger and acquisition play— trade at such a steep discount. And with the market behaving how it’s been lately, I feel like this opportunity will vanish soon. There are some very powerful people who want to see this deal go through, including billionaire investor, Carl Icahn. In addition, just last week I saw a massive $600K smart money options trade—which gives me even more confidence the deal will go through. Now in order for you to receive this special situation alert, you must be [subscribed to the Sniper Report]( You won’t only receive this alert, but you’ll also get 12-months access to my best set it, and forget it, trade ideas. As much as I would love to tell you have time— the market waits for no man or woman. I will be announcing this play any day now. [It’s not too late to get in](. [Don’t miss out on this rare money-grabbing opportunity.]( [It’s yours for the taking.]( Kyle Dennis [Special]( RagingBull, LLC 62 Calef Hwy. #233, Lee, NH 03861 [Click Here to stop receiving emails from kyle@biotechbreakouts.com]( [Unsubscribe from all RagingBull emails]( Neither Kyle Dennis nor RagingBull.com, LLC (publisher of BiotechBreakouts) is registered as an investment adviser nor a broker/dealer with either the U. S. Securities & Exchange Commission or any state securities regulatory authority. Users of this website are advised that all information presented on this website is solely for informational purposes, is not intended to be used as a personalized investment recommendation, and is not attuned to any specific portfolio or to any user's particular investment needs or objectives. The owners, employees and writers of RagingBull.com may engage in securities trading that is discussed or viewed on this website, but all such individuals are buying and selling such securities for their own account. These individuals do not engage in any trades with customers. The buying and selling of securities by these individuals is not part of a regular business of buying and selling securities. Past performance is NOT indicative of future results. Furthermore, such information is not to be construed as an offer to sell or the solicitation of an offer to buy, nor is it to be construed as a recommendation to buy, hold or sell (short or otherwise) any security. All users of this website must determine for themselves what specific investments to make or not make and are urged to consult with their own independent financial advisors with respect to any investment decision. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. All opinions, analyses and information included on this website are based on sources believed to be reliable and written in good faith, but should be independently verified, and no representation or warranty of any kind, express or implied, is made, including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. In addition, we undertake no responsibility to notify such opinions, analyses or information or to keep such opinions, analyses or information current. Also be aware that owners, employees and writers of and for RagingBull.com, LLC may have long or short positions in securities that may be discussed on this website or newsletter, but all such positions are held for such representative’s own account. Past results are not indicative of future profits. This table is accurate, though not every trade is represented. Profits and losses reported are actual figures from the portfolios Kyle Dennis manages on behalf of RagingBull.com, LLC. If you have a current active subscription with Biotech Breakouts you will need to contact us here if you want to cancel your subscription. Opting out of emails does not remove you from your service at BiotechBreakouts.com.

Marketing emails from biotechbreakouts.com

View More
Sent On

31/07/2021

Sent On

31/07/2021

Sent On

17/07/2021

Sent On

09/07/2021

Sent On

08/07/2021

Sent On

08/07/2021

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.